Somavert is a new treatment option for acromegaly

Somavert is a new treatment option for acromegaly in Canada.

Acromegaly is caused by a benign pituitary tumour that results in oversecretion of growth hormone. If left untreated, it can cause serious complications such as disfigurement and blindness.

Somavert (pegvisomant) is for patients who don't respond to surgery, radiation, and/or other medical therapies for acromegaly.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote